| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, April 2007, p. 2499-2511, Vol. 27, No. 7
0270-7306/07/$08.00+0 doi:10.1128/MCB.01088-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Samuel C. K. Chung,1,
Amy K. M. Lam,2
Sidney Tam,3
Sookja K. Chung,2 and
Billy K. C. Chow1*
Department of Zoology,1 Department of Anatomy,2 Division of Clinical Biochemistry, The University of Hong Kong, Pokfulam, Hong Kong SAR, China3
Received 16 June 2006/ Returned for modification 21 July 2006/ Accepted 14 December 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
| MATERIALS AND METHODS |
|---|
|
|
|---|
|
Cellular localization of wild-type and mutant mSCTR in CHO cells. To locate wild-type and mutant mSCTR in transfected cells, cDNAs produced by PCR with primers mSR-ATG and mSRcfc-R1 were inserted into the HindIII and XbaI sites of pcDNA3.1/myc-HisA (Invitrogen), a c-Myc-tagged expression vector, for immunofluorescence studies. CHO cells were cultured on 12-mm glass coverslips and transiently transfected with the c-Myc-tagged receptor constructs. Two days after transfection, cells were fixed with 0.5% paraformaldehyde and permeabilized with phosphate-buffered saline-saponin. After addition of mouse anti-c-Myc monoclonal antibody (9E10; 1:250 dilution; Fisher Scientific Inc.) for 20 h of incubation at 4°C, the cells were washed and incubated with Cy-2 labeled rabbit anti-mouse immunoglobulin G (IgG; 1:200 dilution; Amersham), and the receptors were visualized by confocal microscopy (MRC 600; Bio-Rad Laboratories, Richmond, CA).
Construction of SCTR targeting vector and selection in embryonic stem (ES) cells.
A murine 129Sv genomic DNA library (lambda FIX II library of ES cells at day 3; Stratagene, La Jolla, CA) was screened for the mSCTR gene with the full-length cDNA as the probe (Megaprime DNA labeling kit [Amersham Pharmacia, Buckinghamshire, England]; [
-32P]dCTP, 3,000 Ci/mmol [Amersham Pharmacia]). Phage DNA was extracted from positive tertiary clones by the QIAGEN Lambda Midi Kit (QIAGEN Inc., Santa Clarita, CA), and a 22-kb genomic clone containing part of the mSCTR gene was isolated within which the 7.57-kb XhoI DNA fragment, which spans the region from exon 8 to exon 11, was used to construct the SCTR targeting vector.
A 5.05-kb XbaI/XbaI fragment which contains a part of intron 7 to a part of intron 9 of the mSCTR gene was inserted upstream of the thymidine kinase (tk) gene in gene replacement targeting vector pPNT. A PCR-generated 1.8-kb XhoI/NotI DNA fragment including exon 11 and a portion of introns 10 and 11 was inserted upstream of the neomycin resistance (neo) gene. This SCTR targeting vector, designated pPNT-SCTRko, with the PGK-1 promoter and neo replacing exon 10, was linearized with NotI and electroporated into 129Sv (AB2.2) mouse ES cells. By positive-negative selection, ES cell clones resistant to G418 and fialuridine (Sigma) were expanded in 96-well plates and then screened by two independent PCRs, one detecting the presence of the neo gene, with primers jpxb and neoR1, and the other detecting the absence of the tk gene, with primers jpxE and tkF1. Genomic DNA from the positive clones was digested with StuI and confirmed by Southern blot analysis. The 9.139-kb band in the blot denoted the presence of wild-type SCTR, whereas the 5.142-kb band indicated the presence of a mutated SCTR gene (Fig. 1B).
|
For measuring water consumption and urine output, mice were kept individually in metabolic cages. For water deprivation experiments, water bottles were removed for 2 days. Urine samples were collected by spontaneous voiding before and after the water-deprived period, and kidneys were isolated for the preparation of PM- and intracellular-vesicle (IV)-enriched fractions.
Assays for electrolytes, vasopressin (Vp), and secretin. Urine samples were collected from metabolic cages in a 24-h period, and serum samples were collected by cardiac puncture under basal conditions (unrestricted access to food and water). Urine Na, K, Ca, Cl, urea, and creatinine levels were measured with a Synchron CX5 analyzer (Beckman Instruments, Inc., Fullerton, CA). Serum Na, K, Ca, Cl, urea, and creatinine levels were measured with a Hitachi-747 autoanalyzer (Roche Diagnostics). Urine osmolality was measured by the vapor pressure method, with a Vapro vapor pressure osmometer (Wescor Inc., Logan, Utah). Serum osmolality was measured by the freezing depression method, with an Advanced Micro-Osmometer 3300 (Advanced Instruments, Inc.). Urine and serum Vp levels were measured with a Vp enzyme immunoassay kit (Assay Designs Inc., Ann Arbor, MI). Serum secretin levels were measured with a secretin enzyme immunoassay kit (Phoenix Pharmaceuticals, Inc., Belmont, CA).
Quantitative analyses of renal gene expression.
The expression levels of various genes were measured by real-time PCR with a SYBR green PCR kit (Applied Biosystems). The gene for glyceraldehyde-3-phosphate dehydrogenase was used as an internal standard for normalization, and transcript levels of each gene were quantified with the iCycler iQ Detection System (Bio-Rad, Hercules, CA) according to the manufacturer's instructions. Fluorescence signals were measured at the extension step throughout the amplification process. The specificity of the fluorescence signal was confirmed by melting curve analysis and agarose gel electrophoresis. The threshold cycle (Ct) was determined for each sample and was defined as the fractional cycle number at which the fluorescence signals reached 10 times the standard deviation of the baseline. The expression level of the target gene was determined by the 2
Ct method (24).
Morphological analysis and immunofluorescence staining. For morphological analysis, kidneys from SCTR+/+ and SCTR/ mice were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned (5 to 7 µm), and stained with hematoxylin and eosin and periodic acid-Schiff. For immunohistochemical staining, after deparaffinization, rehydration, and permeabilization in KPBS-BT (200 mg/liter KCl-containing phosphate-buffered saline supplemented with 0.25% bovine serum albumin and 0.1% Triton X-100), sections were blocked in a 12% donkey serum solution and incubated overnight with the primary antibody. For single-antigen staining, a primary antibody against mouse F4/80 (1:50 dilution; rat anti-mouse F4/80 antigen-fluorescein isothiocyanate; Serotec, Oxford, United Kingdom) was applied and sections were washed with KPBS-BT and mounted with 90% glycerol on the next day. For double-immunofluorescence staining, sections were incubated overnight with goat antiserum against AQP2 or the Vp type 2 receptor (V2R) (1:400 dilution; Santa Cruz Biotechnology, Inc.), washed in KPBS-BT, and incubated with Alexa Fluor 488 donkey anti-goat IgG (1:500 dilution; Molecular Probes Inc., Invitrogen). Chicken serum (12%) was then applied, and sections were incubated at 4°C overnight with rabbit anti-mouse secretin receptor antibody (1:200; recently raised in our laboratory with a synthetic peptide [R-A-E-C-L-R-E-L-S-E-E-K-K] that is present in the mouse secretin receptor) (9), followed by the addition of Alexa Fluor 594 chicken anti-rabbit IgG (1:500 dilution; Molecular Probes). Images were observed and captured with the Leica Quantimet 570 computerized image analysis system. To test the specificity of secretin receptor immunostaining, control experiments were performed with renal sections from SCTR/ mice or by liquid phase preabsorption of the antiserum with the synthetic immunizing peptide (0.1 M) for 3 h at room temperature.
Tubule isolation and preparation of membrane fractions. SCTR/ and SCTR+/+ mice (8 to 9 weeks old) were killed by cervical dislocation. Kidneys were rapidly removed; the inner medulla was dissected and finely minced with a razor blade. Ten milliliters of an enzymatic solution (Dulbecco modified Eagle medium-F12 containing 2 mg/ml collagenase, 1 mg/ml hyaluronidase, 0.1 mg/ml pronase, 4.8 mg/ml urea, 7.4 mg/ml NaCl, and 140 mM K-gluconate) was added, and the mixture was incubated at 37°C for 90 min in a shaking water bath top gassed with 95% CO2-5% O2. Thereafter, tubules were pelleted at 800 x g and resuspended in Leibovitz L-15 culture medium containing 80 mM urea and 1% bovine serum albumin. These centrifugation and resuspension steps were repeated three times to remove residual proteases. The kidney tubule preparation was then aliquoted into six-well plates with Leibovitz culture medium topped up to 3 ml with or without 30 min of secretin stimulation at 37°C. After drug treatment, the tubule preparation was pelleted at 800 x g and resuspended in 1 ml of ice-cold isolation solution (250 mM sucrose, 25 mM imidazole, and 10 mM tetraethylammonium with 1 µg/ml leupeptin and 1 mg/ml phenylmethylsulfonyl fluoride). Samples were homogenized and centrifuged at 4,000 x g for 15 min at 4°C to remove large cellular organelles, and the supernatant was collected and recentrifuged at 17,000 x g at 4°C for 30 min to obtain the PM (pellet) and IV (supernatant) fractions.
To assess the functional integrity of secretin receptors after enzymatic digestion in the isolation procedure, the kidney tubule preparation was stimulated with graded concentrations of secretin (1010 to 106 M), followed by cAMP assay.
Western blot and densitometry analyses. Kidneys from SCTR/ and SCTR+/+ mice were homogenized and centrifuged at 4,000 x g for 15 min at 4°C. Protein concentration was determined, and the expression levels of AQP1, -2, -3, and -4 were measured by Western blotting, followed by densitometric analysis. Protein samples were separated in parallel in two 12% sodium dodecyl sulfate-polyacrylamide minigels. One gel was stained with Coomassie blue, and the other gel was used for immunoblotting.
For analyzing AQP2 expression after secretin treatment, PM fractions were loaded at 9 µg/well and IV fractions were loaded at 50 µg/well. This arrangement gave similar intensities of the AQP2 bands; thus, a more accurate estimation of the PM-to-IV ratio could be obtained. To measure various AQP levels in crude protein extracts prepared from wild-type and knockout animals, samples (9 µg/well) were separated in minigels and transferred onto Hybond-C extra nitrocellulose membranes (Amersham Biosciences) by electroelution for 2 h at 100 V with a Bio-Rad Mini Protean II transblot apparatus. The blots were blocked for 1 h with 5% skim milk in PBST (80 mM Na2HPO4, 20 mM NaH2PO4, 100 mM NaCl, 0.1% Tween 20, pH 7.5) and then incubated overnight at 4°C with the appropriate antibody (1:200 AQP1, 1:430 AQP2, 1:500 AQP3, or 1:200 AQP4; Santa Cruz Biotechnology, Santa Cruz, CA). After three washes in PBST, the blots were incubated for 1 h with horseradish peroxidase-conjugated secondary antibody against rabbit or goat IgG (1:8,000 or 1:5,800 dilution, respectively). Positive signals were produced by the enhanced chemiluminescence system (Amersham Biosciences), and enhanced chemiluminescence films were scanned and analyzed with the Easygel software to give the PM/IV ratio.
Statistical analysis. For quantitative real-time PCR analysis, data are shown as the mean ± the standard error of the mean (SEM) from at least three independent experiments, each in triplicate. All data were analyzed by one-way analysis of variance, followed by a Dunnett test with the computer software PRISM (version 3.0; GraphPad Software Inc., San Diego, CA). For metabolic experiments and expression studies, statistical significance was determined with the unpaired Student t test.
| RESULTS |
|---|
|
|
|---|
|
Function of secretin and its receptor in the urinary system. SCTR+/+, SCTR+/, and SCTR/ mice were born at the expected 1:2:1 Mendelian ratio from the heterozygous parents, suggesting that no embryonic lethality was associated with the null mutant. SCTR/ mice showed similar body weights at 12 weeks compared to those of their wild-type littermates (SCTR+/+, 26.5 ± 1.5 g; SCTR/, 25.5 ± 1.0 g), indicating no growth abnormality. Their general appearance and litter sizes were also similar to those of the wild-type mice.
To study putative renal functions of the receptor, kidneys from SCTR+/+ and SCTR/ mice were examined. The kidney/body weight ratio of SCTR/ mice was significantly higher than that of the wild-type littermates (1.65-fold; 0.620 ± 0.034 g and 1.021 ± 0.086 g for SCTR+/+ and SCTR/, respectively; n = 15). Histological examination showed that SCTR/ mice exhibited abnormalities in the renal cortex, as well as in the medulla, characterized by increased mesangial area, enlarged urinary space, and frequent tubular dilation and hypertrophy in the collecting tubules of the medullary region (Fig. 3A), suggesting that they might have altered glomerular filtration and/or renal reabsorption processes. For this reason, we also measured water intake, urine output, and concentrations of Vp and various electrolytes in the urine and serum samples of euhydrating mice. As illustrated in Fig. 3B, the urine osmolality of SCTR/ mice was significantly lower (decreased 17.3%) than that of SCTR+/+ mice, indicating that the SCTR/ animals produced more-diluted urine. Additionally, reductions in urinary Na+ and K+ excretion, as well as urea and creatinine levels, in the urine samples were also observed in the SCTR/ mice. Nevertheless, serum concentrations of electrolyte, urea, and creatinine and creatinine clearance were not significantly different in SCTR+/+ and SCTR/ mice. In euhydrating animals, serum Vp levels were slightly higher in SCTR/ mice, and this is consistent with the higher Vp transcript levels in the hypothalamuses of SCTR/ mice (1.54-fold ± 0.19-fold; P < 0.05; n = 20). These data therefore suggest that the observed phenotypes developed by SCTR/ mice were unlikely due to defects in Vp biosynthesis and/or secretion.
|
Renal gene expression. The polyuric phenotype developed in SCTR/ mice suggests possible biochemical changes in the kidney tubules. Figure 4A compares the expression levels of various genes, including those for secretin, aquaporins, Vp receptor, and various inflammatory markers in SCTR+/+ and SCTR/ mouse kidneys. Quantification by real-time reverse transcription-PCR revealed significant reductions in the transcript levels of secretin, AQP2, and AQP4, but not V2R, in the SCTR/ kidney. This indicated that the impaired urine-concentrating ability of SCTR/ mice is due not to reduced levels of V2R, and hence an altered response to Vp, but to reduced AQP2 and AQP4 expression levels. In accordance with these results, Western immunoblotting also revealed reduced expression of these aquaporins in the transgenic animals (Fig. 4B). As AQP2 and AQP4 were present on the apical and basolateral membranes, respectively, of the collecting tubules (33), reductions in both transcript and protein levels of these water channels were in agreement with the observed phenotypes developed by SCTR/ animals.
|
Effects of secretin on AQP2 trafficking in renal tubules. To understand further the direct actions of secretin on kidney tubules, we used renal sections from SCTR+/+ mice, with SCTR/ mice as negative controls, to examine the localization of SCTR, AQP2, and Vp receptor V2R (Fig. 5). Consistent with a previous report (7), immunohistochemical staining revealed the presence of SCTR in the renal medulla, where it was coexpressed with V2R in the cuboidal epithelium of the collecting ducts and in the simple columnar epithelium of the ducts of Bellini. In these regions, SCTR is predominantly found on the basolateral membrane while AQP2 is localized on the apical membrane. Additionally, we also observed the presence of SCTR in the proximal tubules and the ascending thick segment of the loop of Henle, suggesting a possible role for secretin in regulating Na+ reabsorption.
|
|
3.93-fold, respectively). These data clearly demonstrate that the induced expression and redistribution of AQP2 during water deprivation were at least partially dependent on SCTR, which represents an additional mechanism of the Vp-V2R axis. Serum secretin levels during water deprivation. To substantiate the role of secretin in regulating renal water transport in response to water deprivation, we anticipated changes in serum secretin levels under hyperosmotic conditions. To examine this, we collected blood samples from SCTR+/+ and SCTR/ mice that had been deprived of drinking water for 2 days. In both SCTR+/+ and SCTR/ mice, circulating immunoreactive secretin levels were increased after water restriction (1.60-fold ± 0.03-fold and 1.58-fold ± 0.02-fold, respectively; P < 0.05) (Fig. 7). These elevations, however, were not significantly different in SCTR+/+ and SCTR/ mice, indicating that the differences in AQP2 trafficking and expression between SCTR+/+ and SCTR/ mice under water-deprived conditions are likely direct consequences of inadequate renal responses to secretin in the transgenic animals. Therefore, this finding, which shows an increase in serum secretin under hyperosmotic condition, affirms the osmoregulatory role of secretin hypothesized in this study.
|
| DISCUSSION |
|---|
|
|
|---|
In this study, SCTR/ mice were generated by deleting exon 10 of the gene, which encodes the third endoloop of the receptor, which is essential for G protein coupling and signal transduction. The renal morphologies observed in our studies, however, were not reported in the other transgenic secretin receptor mice that had exon 1 replaced with the lacZ reporter and a PGKneobpA selection marker (35). The discrepancies in our data are possibly due to differences in genetic background and/or the targeting strategies used in generating the transgenic animals. In our study, we used mice of the N5 generation while Nishijima et al. used mice that had a C57BL-6Jx129S7 mixed genetic background and gave no information regarding which generation of mice was used for experimentation. It is well documented that the genetic background of transgenic mice could influence the phenotypes developed and hence could sometimes lead to faulty interpretations of data (10, 14, 15, 23, 46). In addition, with the help of a secretin receptor antiserum recently raised in our laboratory (9), we were able to show genuine secretin receptor knockout in our mice, while in their study, they deleted exon 1, which should encode the signal peptide. Without any supporting data from immunohistochemical staining, it is therefore still possible that some functional secretin receptors are present in these animals. Further experiments are needed to investigate and clarify the phenotypic differences observed in these two types of secretin receptor knockout mice.
The observation of phenotypes such as polydipsia and polyuria in SCTR/ mice raises the possibility that secretin might play a role in water homeostasis. In fact, the role of secretin and its receptor in regulating renal functions has been suggested but not fully substantiated in the past. One of the reasons is that the expression and localization of secretin receptors in the kidney were controversial. Previously, our laboratory showed that SCTR mRNA is expressed in the human kidney by Northern blot analysis (8) whereas Ulrich et al. (41) reported finding no expression of this receptor in the rat kidney by RNase protection assay. Charlton et al., on the other hand, found a high density of [125I]secretin binding sites in the renal medulla (7). Moreover, inconsistent findings on the renal function of secretin have been reported. Early studies suggested a diuretic role for this peptide to increase renal excretion of water, bicarbonate, sodium, potassium, and calcium in normal humans and dogs (2, 3, 42, 43), whereas another study demonstrated an antidiuretic action of secretin when administered intravenously to anesthetized hydrated rats (7). In the latter study, secretin was shown to act on the receptor on the renal medulla to decrease urine output through the activation of adenylate cyclase, and this effect is as potent as that of Vp in Brattleboro rats. Consistent with these observations, the present study showed altered AQP2 expression and trafficking in SCTR/ mice under water deprivation compared to that in SCTR+/+ mice. These data not only corroborate the urine-concentrating ability and antidiuretic roles of secretin but also provide evidence, for the first time, that secretin could be one of the Vp-independent mechanisms controlling water homeostasis. Compatible with this idea, plasma secretin levels were found to increase three- to sixfold under stress (37), which is consistent with our finding that water restriction induces 5.66-fold ± 0.59-fold and 1.60-fold ± 0.03-fold plasma secretin level increases in rats (data not shown) and mice, respectively. Secretin, a classical hormone that controls the cellular transportation of electrolytes, is therefore a potential factor controlling AQP2 trafficking in the kidney and could serve as a potential candidate in treating X-linked NDI with defective V2R signaling. Consonant with this, SCTR/ mice display pathological symptoms that are characteristics of NDI, such as polydipsia and excessive urination, glomerular hypertrophy, dilation of tubules in the renal medulla, down-regulation of AQP2 and AQP4 expression, up-regulation of E-selectin and OPN, and significant elevation of plasma Vp levels (11, 16-18, 20, 26, 32, 39, 45). Together with reported effects of secretin on insulin secretion (12, 13), alteration of the synthesis and/or secretion of this hormone might contribute to renal and metabolic perturbations observed in diabetes. Therefore, further investigation of secretin as a potential target for prevention and/or therapeutic intervention of this disease is warranted.
| ACKNOWLEDGMENTS |
|---|
This work was supported by Hong Kong government RGC grants HKU7501/05 M and HKU7384/04 M to Billy K. C. Chow.
| FOOTNOTES |
|---|
Published ahead of print on 5 February 2007. ![]()
J. Y. S. Chu and S. C. K. Chung contributed equally to the overall design and execution of the experiments described here. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Barbezat, G. O., J. I. Isenberg, and M. I. Grossman. 1972. Diuretic action of secretin in dog. Proc. Soc. Exp. Biol. Med. 139:211-215.[Medline]
3. Baron, D. N., F. Newman, and A. Warrick. 1958. The effects of secretin on urinary volume and electrolytes in normal subjects and patients with chronic pancreatic disease. Experientia 14:30-32.
4. Bayliss, W. M., and E. H. Starling. 1902. The mechanism of pancreatic secretion. J. Physiol. (London) 28:325-353.
5. Bradbury, N. A., and R. J. Bridges. 1994. Role of membrane trafficking in plasma membrane solute transport. Am. J. Physiol. 267:C1-C24.
6. Chan, K. Y., R. T. Pang, and B. K. Chow. 2001. Functional segregation of the highly conserved basic motifs within the third endoloop of the human secretin receptor. Endocrinology 142:3926-3934.
7. Charlton, C. G., R. Quirion, G. E. Handelmann, R. L. Miller, R. T. Jensen, M. S. Finkel, and T. L. O'Donohue. 1986. Secretin receptors in the rat kidney: adenylate cyclase activation and renal effects. Peptides 7:865-871.[CrossRef][Medline]
8. Chow, B. K. 1995. Molecular cloning and functional characterization of a human secretin receptor. Biochem. Biophys. Res. Commun. 212:204-211.[CrossRef][Medline]
9. Chow, B. K., K. H. Cheung, E. M. Tsang, M. C. Leung, S. M. Lee, and P. Y. Wong. 2004. Secretin controls anion secretion in the rat epididymis in an autocrine/paracrine fashion. Biol. Reprod. 70:1594-1599.
10. Crusio, W. E. 2004. Flanking gene and genetic background problems in genetically manipulated mice. Biol. Psychiatry 56:381-385.[CrossRef][Medline]
11. Davis, F. B., and P. J. Davis. 1981. Water metabolism in diabetes mellitus. Am. J. Med. 70:210-214.[CrossRef][Medline]
12. Dupré, J., D. J. Chisholm, T. J. McDonald, and A. Rabinovitch. 1975. Effects of secretin on insulin secretion and glucose tolerance. Can. J. Physiol. Pharmacol. 53:1115-1121.[Medline]
13. Enk, B. 1976. Secretin-induced insulin response. II. Dose-response relation. Acta Endocrinol. (Copenhagen) 82:312-317.
14. Gerlai, R. 1996. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci. 19:177-181.[CrossRef][Medline]
15. Gerlai, R. 2001. Gene targeting: technical confounds and potential solutions in behavioral brain research. Behav. Brain Res. 125:13-21.[CrossRef][Medline]
16. Hirata, K., K. Shikata, M. Matsuda, K. Akiyama, H. Sugimoto, M. Kushiro, and H. Makino. 1998. Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 41:185-192.[CrossRef][Medline]
17. Hsieh, T. J., R. Chen, S. L. Zhang, F. Liu, M. L. Brezniceanu, C. I. Whiteside, I. G. Fantus, J. R. Ingelfinger, P. Hamet, and J. S. Chan. 2006. Upregulation of osteopontin gene expression in diabetic rat proximal tubular cells revealed by microarray profiling. Kidney Int. 69:1005-1015.[CrossRef][Medline]
18. Iwasaki, Y., K. Kondo, T. Murase, H. Hasegawa, and Y. Oiso. 1996. Osmoregulation of plasma vasopressin in diabetes mellitus with sustained hyperglycemia. J. Neuroendocrinol. 8:755-760.[CrossRef][Medline]
19. Jeon, U. S., K. W. Joo, K. Y. Na, Y. S. Kim, J. S. Lee, J. Kim, G. H. Kim, S. Nielsen, M. A. Knepper, and J. S. Han. 2003. Oxytocin induces apical and basolateral redistribution of aquaporin-2 in rat kidney. Nephron Exp. Nephrol. 93:e36-e45.[CrossRef][Medline]
20. Leung, J. C., L. Y. Chan, A. W. Tsang, S. C. Tang, and K. N. Lai. 2005. Differential expression of aquaporins in the kidneys of streptozotocin-induced diabetic mice. Nephrology (Carlton) 10:63-72.
21. Li, C., W. Wang, S. N. Summer, M. A. Cadnapaphornchai, S. Falk, F. Umenishi, and R. W. Schrier. 2006. Hyperosmolality in vivo upregulates aquaporin 2 water channel and Na-K-2Cl co-transporter in Brattleboro rats. J. Am. Soc. Nephrol. 17:1657-1664.
22. Li, X. M., and L. J. Shapiro. 1993. Three-step PCR mutagenesis for linker scanning. Nucleic Acids Res. 21:3745-3748.
23. Linder, C. C. 2006. Genetic variables that influence phenotype. ILAR J. 47:132-140.[Medline]
24. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2
Ct method. Methods 25:402-408.[CrossRef][Medline]
25. Lorenz, D., A. Krylov, D. Hahm, V. Hagen, W. Rosenthal, P. Pohl, and K. Maric. 2003. Cyclic AMP is sufficient for triggering the exocytic recruitment of aquaporin-2 in renal epithelial cells. EMBO Rep. 4:88-93.[CrossRef][Medline]
26. Makaryus, A. N., and S. I. McFarlane. 2006. Diabetes insipidus: diagnosis and treatment of a complex disease. Clevel. Clin. J. Med. 73:65-71.[Medline]
27. Marinelli, R. A., L. Pham, P. Agre, and N. F. LaRusso. 1997. Secretin promotes osmotic water transport in rat cholangiocytes by increasing aquaporin-1 water channels in plasma membrane. Evidence for a secretin-induced vesicular translocation of aquaporin-1. J. Biol. Chem. 272:12984-12988.
28. Marinelli, R. A., P. S. Tietz, L. D. Pham, L. Rueckert, P. Agre, and N. F. LaRusso. 1999. Secretin induces the apical insertion of aquaporin-1 water channels in rat cholangiocytes. Am. J. Physiol. 276:G280-G286.
29. Matsumura, Y., S. Uchida, T. Rai, S. Sasaki, and F. Marumo. 1997. Transcriptional regulation of aquaporin-2 water channel gene by cAMP. J. Am. Soc. Nephrol. 8:861-867.[Abstract]
30. Michimata, M., S. Nogae, M. Ohta, S. Kaizuma, Y. Imai, S. Ito, and M. Matsubara. 2000. Topographic distribution of aquaporin 2 mRNA in the kidney of dehydrated rats. Exp. Nephrol. 8:28-36.[CrossRef][Medline]
31. Migeon, J. C., and N. M. Nathanson. 1994. Differential regulation of cAMP-mediated gene transcription by m1 and m4 muscarinic acetylcholine receptors. Preferential coupling of m4 receptors to Gi
-2. J. Biol. Chem. 269:9767-9773.
32. Narumi, S., M. L. Onozato, A. Tojo, S. Sakamoto, and T. Tamatani. 2001. Tissue-specific induction of E-selectin in glomeruli is augmented following diabetes mellitus. Nephron 89:161-171.[CrossRef][Medline]
33. Nejsum, L. N. 2005. The renal plumbing system: aquaporin water channels. Cell. Mol. Life Sci. 62:1692-1706.[CrossRef][Medline]
34. Nielsen, S., J. Frokiaer, D. Marples, T. H. Kwon, P. Agre, and M. A. Knepper. 2002. Aquaporins in the kidney: from molecules to medicine. Physiol. Rev. 82:205-244.
35. Nishijima, I., T. Yamagata, C. M. Spencer, E. J. Weeber, O. Alekseyenko, J. D. Sweatt, M. Y. Momoi, M. Ito, D. L. Armstrong, D. L. Nelson, R. Paylor, and A. Bradley. 2006. Secretin receptor-deficient mice exhibit impaired synaptic plasticity and social behavior. Hum. Mol. Genet. 15:3241-3250.
36. Noda, Y., and S. Sasaki. 2005. Trafficking mechanism of water channel aquaporin-2. Biol. Cell 97:885-892.[CrossRef][Medline]
37. Oektedalen, O., P. K. Opstad, and O. B. Schaffalitzky de Muckadell. 1982. Secretina new stress hormone? Regul. Pept. 4:213-219.[CrossRef][Medline]
38. Parvin, M. N., S. Kurabuchi, K. Murdiastuti, C. Yao, C. Kosugi-Tanaka, T. Akamatsu, N. Kanamori, and K. Hosoi. 2005. Subcellular redistribution of AQP5 by vasoactive intestinal polypeptide in the Brunner's gland of the rat duodenum. Am. J. Physiol. Gastrointest. Liver Physiol. 288:G1283-G1291.
39. Tallroth, G., E. Ryding, R. Ekman, and C. D. Agardh. 1992. The response of regulatory peptides to moderate hypoglycaemia of short duration in type 1 (insulin-dependent) diabetes mellitus and in normal man. Diabetes Res. 20:73-85.[Medline]
40. Tietz, P. S., M. A. McNiven, P. L. Splinter, B. Q. Huang, and N. F. Larusso. 2006. Cytoskeletal and motor proteins facilitate trafficking of AQP1-containing vesicles in cholangiocytes. Biol. Cell 98:43-52.[CrossRef][Medline]
41. Ulrich, C. D., P. Wood, E. M. Hadac, E. Kopras, D. C. Whitcomb, and L. J. Miller. 1998. Cellular distribution of secretin receptor expression in rat pancreas. Am. J. Physiol. 275:G1437-G1444.
42. Viteri, A. L., J. W. Poppell, J. M. Lasater, and W. P. Dyck. 1975. Renal response to secretin. J. Appl. Physiol. 38:661-664.
43. Waldum, H. L., J. A. Sundsfjord, U. Aanstad, and P. G. Burhol. 1980. The effect of secretin on renal haemodynamics in man. Scand. J. Clin. Lab. Investig. 40:475-478.[Medline]
44. Wilke, C., S. Sheriff, M. Soleimani, and H. Amlal. 2005. Vasopressin-independent regulation of collecting duct aquaporin-2 in food deprivation. Kidney Int. 67:201-216.[CrossRef][Medline]
45. Yang, B., D. Zhao, L. Qian, and A. S. Verkman. 2006. Mouse model of inducible nephrogenic diabetes insipidus produced by floxed aquaporin-2 gene deletion. Am. J. Physiol. Renal Physiol. 291:465-472.
46. Yoshiki, A., and K. Moriwaki. 2006. Mouse phenome research: implications of genetic background. ILAR J. 47:94-102.[Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|